



Fouad Namouni, M.D.
Head of Oncology Development

Fouad Namouni, M.D., is Head of Oncology Development at Bristol-Myers Squibb (BMS). In this position, he has responsibility for ensuring the safe and appropriate use of the company's products and for creating a comprehensive portfolio strategy for Oncology and driving product development plans from the early stage of clinical development through commercialization. He is accountable to Tom Lynch, Chief Scientific Officer, and is a member of the R&D Executive Leadership Team and the Commercial Leadership Team.

Over the course of his career at BMS, Fouad has demonstrated highly successful strategic and visionary leadership in oncology and immuno-oncology drug development and medical affairs at both national and international levels.

Before taking on his current role, Fouad was Head of Development for Opdivo® and Yervoy®. Under his leadership, Opdivo received approval for the treatment of metastatic squamous non-small cell lung cancer (NSCLC) and unresectable or metastatic melanoma, as well as expanded approval in previously treated NSCLC in the United States and European markets. Yervoy received approval for the adjuvant treatment of stage III melanoma, and Opdivo plus Yervoy was approved for the treatment of metastatic melanoma.

Prior to this, Fouad was responsible for the development of the epidermal growth factor inhibitor Erbitux® and the IgG1 monoclonal antibody necitumumab. He also served as Global, U.S. and E.U. medical lead in several BMS oncology projects. Fouad joined BMS France in 1999 as Taxol® life cycle manager.

Earlier in his career, Fouad was a pediatric oncologist at Institut Curie in Paris, France, where his focus was on developing agents for the treatment of pediatric tumors. He received his medical degree from the University of Annaba Medical School in Algeria, and Pediatrics degree from Université Rene Descartes in Paris, France. He also received his Pediatric Oncology and Hematology degree and a M.S. in clinical and experimental pharmacology from Université Paris-Sud in France.